The D2 dopamine receptor A1 allele and opioid dependence: Association with heroin use and response to methadone treatment

Bruce R Lawford; Ross Young; Ernest P Noble; Joanne Sargent; John Rowell; Susan Shadforth; Xuxian Zhang; Terry Ritchie

doi:10.1002/1096-8628(20001009)96:5<592::AID-AJMG3>3.0.CO;2-Y

Back

The D2 dopamine receptor A1 allele and opioid dependence: Association with heroin use and response to methadone treatment

Journal article

Peer reviewed

The D2 dopamine receptor A1 allele and opioid dependence: Association with heroin use and response to methadone treatment

Bruce R Lawford, Ross Young, Ernest P Noble, Joanne Sargent, John Rowell, Susan Shadforth, Xuxian Zhang and Terry Ritchie

American Journal of Medical Genetics, Vol.96(5), pp.592-598

2000

DOI: https://doi.org/10.1002/1096-8628(20001009)96:5<592::AID-AJMG3>3.0.CO;2-Y

Files and links (1)

url

https://doi.org/10.1002/1096-8628(20001009)96:5<592::AID-AJMG3>3.0.CO;2-YView

Published Version

Abstract

heroin

opioid dependence

dopamine

methadone

treatment outcome

D2 dopamine receptor gene

A total of 95 Caucasian opioid-dependent patients were followed over a one-year period in an outpatient methadone treatment program. The frequency of the TaqI A 1 allele of the D 2 dopamine receptor (DRD2) gene was 19.0% in these patients compared with 4.6% in controls free of past and current alcohol and other drug abuse and free of family history of alcohol and other drug abuse (p = 0.009). Twenty-two of these patients dropped out of the methadone program (Group A), 54 had a successful treatment (Group B), and 19 had a poor treatment (Group C) outcome. The frequency of the A 1 allele was highest in Group C (42.1%), followed by Group A (22.7%) and was lowest in Group B (9.3%). The more than fourfold higher frequency of the A 1 allele in the poor treatment outcome group compared with the successful treatment outcome group was significant (p = 0.00002). Moreover, the average use of heroin (grams/day) during the year prior to study entry was more than twice as great in patients with the A 1 + allele (A 1 /A 1 or A 1 /A 2 genotype) than those with the A 1 − allele (A 2 /A 2 genotype) (A 1 + allele = 0.55 ± 0.10, A 1 − allele = 0.25 ± 0.05; p = 0.003). The results indicate that DRD2 variants are predictors of heroin use and subsequent methadone treatment outcome and suggest a pharmacogenetic approach to the treatment of opioid dependence.

Details

Title: The D2 dopamine receptor A1 allele and opioid dependence: Association with heroin use and response to methadone treatment
Authors: Bruce R Lawford (Author) - University of Queensland
Ross Young (Author) - University of Queensland
Ernest P Noble (Author) - University of California Los Angeles
Joanne Sargent (Author) - University of Queensland
John Rowell (Author) - Royal Brisbane Hospital
Susan Shadforth (Author) - Greenslopes Private Hospital
Xuxian Zhang (Author) - University of California Los Angeles
Terry Ritchie (Author) - University of California Los Angeles
Publication details: American Journal of Medical Genetics, Vol.96(5), pp.592-598; 7
Publisher: John Wiley & Sons, Inc
DOI: 10.1002/1096-8628(20001009)96:5<592::AID-AJMG3>3.0.CO;2-Y
ISSN: 1096-8628
Organisation Unit: University of the Sunshine Coast, Queensland; Office of the Deputy Vice-Chancellor (Research and Innovation)
Language: English
Record Identifier: 99551001502621
Output Type: Journal article

Metrics

13 Record Views

123 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Genetics & Heredity

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites